Smith v. Bayer Corp.

131 S. Ct. 2368, 180 L. Ed. 2d 341, 564 U.S. 299, 2011 U.S. LEXIS 4559
Supreme Court of the United States·Decided June 16, 2011·No. 09-1205·Published·Cited by 393 cases

Opinion

*302 Justice Kagan

delivered the opinion of the Court. *

In this case, a Federal District Court enjoined a state court from considering a plaintiff’s request to approve a class action. The District Court did so because it had earlier denied a motion to certify a class in a related case, brought by a different plaintiff against the same defendant alleging similar claims. The federal court thought its injunction appropriate to prevent relitigation of the issue it had decided.

We hold to the contrary. In issuing this order to a state court, the federal court exceeded its authority under the “relitigation exception” to the Anti-Injunction Act. That statutory provision permits a federal court to enjoin a state proceeding only in rare cases, when necessary to “protect or effectuate [the federal court’s] judgments.” 28 U. S. C. §2283. Here, that standard was not met for two reasons. First, the issue presented in the state court was not identical to the one decided in the federal tribunal. And second, the plaintiff in the state court did not have the requisite connection to the federal suit to be bound by the District Court’s judgment.

I

Because the question before us involves the effect of a former adjudication on this case, we begin our statement of the facts not with this lawsuit, but with another. In August 2001, George McCollins sued respondent Bayer Corporation in the Circuit Court of Cabell County, West Virginia, asserting various state-law claims arising from Bayer’s sale of an allegedly hazardous prescription drug called Baycol (which Bayer withdrew from the market that same month). McCol-lins contended that Bayer had violated West Virginia’s consumer protection statute and the company’s express and im *303 plied warranties by selling him a defective product. And pursuant to West Virginia Rule of Civil Procedure 23 (2011), MeCollins asked the state court to certify a class of West Virginia residents who had also purchased Baycol, so that the case could proceed as á class action.

Approximately one month later, the suit now before us began in a different part of West Virginia. Petitioners Keith Smith and Shirley Sperlazza (Smith for short) filed state-law claims against Bayer, similar to those raised in MeCollins’ suit, in the Circuit Court of Brooke County, West Virginia. And like MeCollins, Smith asked the court to certify under West Virginia’s Rule 23 a class of Baycol purchasers residing in the State. Neither Smith nor MeCollins knew about the other’s suit.

In January 2002, Bayer removed MeCollins’ case to the United States District Court for the Southern District of West Virginia on the basis of diversity jurisdiction. See 28 U. S. C. §§ 1332, 1441. The case was then transferred to the District of Minnesota pursuant to a preexisting order of the Judicial Panel on Multi-District Litigation, which had consolidated all federal suits involving Baycol (numbering in the tens of thousands) before a single District Court Judge. See §1407. Bayer, however, could not remove Smith’s case to federal court because Smith had sued several West Virginia defendants in addition to Bayer, and so the suit lacked complete diversity. See § 1441(b). 1 Smith’s suit thus remained in the state courthouse in Brooke County.

Over the next six years, the two cases proceeded along their separate pretrial paths at roughly the same pace. By 2008, both courts were preparing to turn to their respective plaintiffs’ motions for class certification. The Federal District Court was the first to reach a decision.

*304 Applying Federal Rule of Civil Procedure 23, 2 the District Court declined to certify McCollins’ proposed class of West Virginia Baycol purchasers. The District Court’s reasoning proceeded in two steps. The court first ruled that, under West Virginia law, each plaintiff would have to prove “actual injury” from his use of Baycol to recover. App. to Pet. for Cert. 44a. The court then held that because the necessary showing of harm would vary from plaintiff to plaintiff, “individual issues of fact predominate^]” over issues common to all members of the proposed class, and so the case was not suitable for class treatment. Id., at 45a. In the same order, the District Court also dismissed McCollins’ claims on the merits in light of his failure to demonstrate physical injury from his use of Baycol. McCollins chose not to appeal.

Although McCollins’ suit was now concluded, Bayer asked the District Court for another order based upon it, this one affecting Smith’s case in West Virginia. In a motion — receipt of which first apprised Smith of McCollins’ suit — Bayer explained that the proposed class in Smith’s ease was identical to the one the federal court had just rejected. Bayer therefore requested that the federal court enjoin the West Virginia state court from hearing Smith’s motion to certify a class. According to Bayer, that order was appropriate to protect the District Court’s judgment in McCollins’ suit denying class certification. The District Court agreed and granted the injunction.

The Court of Appeals for the Eighth Circuit affirmed. In re Baycol Prods. Litigation, 593 F. 3d 716 (2010). The court noted that the Anti-Injunction Act generally prohibits federal courts from enjoining state court proceedings. But the court held that the Act’s relitigation exception authorized *305 the injunction here because ordinary rules of issue preclusion barred Smith from seeking certification of his proposed class. According to the court, Smith was invoking a similar class action rule as McCollins had used to seek certification “of the same class” in a stdt alleging “the same legal theories,” id., at 724; the issue in the state court therefore was “sufficiently identical” to the one the federal court had decided to warrant preclusion, ibid. In addition, the court held, the parties in the two proceedings were sufficiently alike: Because Smith was an unnamed member of the class McCollins had proposed, and because their “interests were aligned,” Smith was appropriately bound by the federal court’s judgment. Ibid.

Free access — add to your briefcase to read the full text and ask questions with AI

Smith v. Bayer Corp., 131 S. Ct. 2368, 180 L. Ed. 2d 341, 564 U.S. 299, 2011 U.S. LEXIS 4559 (U.S. 2011).

131 S. Ct. 2368 (Smith v. Bayer Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Gardner v. Levy
D. New Mexico, 2025
Trump v. CASA, Inc.
606 U.S. 831 (Supreme Court, 2025)
Mongalo v. Crocs, Inc.
N.D. California, 2025
Ameral v. Vinning
D. Massachusetts, 2024
Staub v. Nietzel
W.D. Kentucky, 2022
John Petitta v. 3M Company
Eighth Circuit, 2021
Nix v. Major League Baseball
S.D. New York, 2020
Richard Tredinnick v. Jackson National Life
954 F.3d 240 (Fifth Circuit, 2020)
Berroteran v. Superior Court
California Court of Appeal, 2019
Gembarski v. PartsSource, Inc. (Slip Opinion)
2019 Ohio 3231 (Ohio Supreme Court, 2019)
Zacarias v. Official Stanford Int'l Bank, Ltd.
931 F.3d 382 (Fifth Circuit, 2019)
Seven Z Enters., Inc. v. Giant Eagle, Inc.
379 F. Supp. 3d 455 (W.D. Pennsylvania, 2019)